VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

Suzanne A. W. Fuqua, PhD
Published: Monday, Aug 18, 2014

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Fuqua says there is a fairly high frequency of this mutation in metastatic breast cancers. These mutations are estrogen independent, meaning that hormones are not needed to activate the receptor. The clinical assumption is that the mutation would confer resistance to an aromatase inhibitor, Fuqua says. However, there is no direct clinical evidence of this because the majority of patients that have been examined have undergone multiple rounds of hormonal therapy.


Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Fuqua says there is a fairly high frequency of this mutation in metastatic breast cancers. These mutations are estrogen independent, meaning that hormones are not needed to activate the receptor. The clinical assumption is that the mutation would confer resistance to an aromatase inhibitor, Fuqua says. However, there is no direct clinical evidence of this because the majority of patients that have been examined have undergone multiple rounds of hormonal therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x